Report
Oussema Denguir

Poxel : Poxel beefs up its pipeline beyond the field of diabetes – primarily in NASH

>Imeglimin, the group’s most advanced asset - Poxel has in recent months managed to secure the future development of what is currently its main asset, imeglimin in the field of diabetes, by signing two partnership agreements with Sumitomo Dainippon in Japan (€ 36m in upfront fees / up to € 219m in milestone payments / gradual royalty payments in the double digits) and with Roivant Sciences for the US and Europe primarily (€ 28m in upfront fees / up to € 486m in milest...
Underlying
Poxel SA

Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch